10 April - 12 April 2024

40th SCI Process Development Symposium

Organised by:

SCI's Fine Chemicals Group

Churchill College, Cambridge, UK

Registration Closed

This event is currently unavailable for registration.

Synopsis

Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering.

The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.  


Attendees
The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development. 
Sponsorship and Exhibition

For further information and prices, please email conferences@soci.org.


Accommodation

Accommodation is now sold out


Programme

Wednesday 10 April

11.00
Registration and refreshments
12.15
Lunch and exhibition
CHAIRPERSON: David Lathbury, Astute chemical development consulting Ltd, UK
13.25
Opening remarks
13.30
The largest small molecule: How chemistry enabled the discovery and development of PCSK9 inhibitor MK-0616
Dr David Thaisrivongs, MSD, USA
14.10
A reluctant process chemist – A review of key projects in a 35-year career
Dr Ian Lennon, Chiralquest, UK
14.50
From early phase to full scale manufacturing. An overview of biocatalysis at Novartis pharma
Thierry Schlama, Novartis Basel, Switzerland
15.30
Refreshment break and exhibition
CHAIRPERSON: Max Espensen, Pharmaron, UK
16.10
Adventures in the development of complex pharmaceuticals
Dr Francisco Gonzalez Bobes, Bristol-Myers Squibb, USA
16.50
Development of a large-scale photoredox fluorodecarboxylation of aliphatic carboxylic acids
Dr Aaron Dumas, Pharmaron Hoddesdon, UK
17.20
Closing remarks
17.30
Wine reception sponsored by ChiralQuest (until 18.15)
19.00
Dinner for residents of the college

Thursday 11 April

CHAIRPERSON: Hilmar Weinmann, Johnson & Johnson Innovative Medicine, Belgium
09:00
Minimizing hazards and risks in chemical process development: Structure-related reactivity investigation of five-membered cyclic sulfamidates
Dr Michael Parmentier, Novartis, Switzerland
09.40
The impact of bringing development capabilities into discovery phase in finding long-acting RSV PreP inhibitors
Kiran Matcha, Johnson & Johnson Innovative Medicine, Belgium
10.20
Refreshment break and exhibition
CHAIRPERSON: Robert Walton, Pfizer, UK
10.50
The Applications of X-Ray Fluorescence across Chemical Process Development in the Pharmaceutical Industry
Chloe Markham, GlaxoSmithKliine, UK
11.30
Nitrosamines, the journey so far
Dr Gair Ford, AstraZeneca, UK
12.10
Lunch and exhibition
13.10
Resolution of racemates: From classical to contemporary
Dr Michel Leeman, Symeres, The Netherlands
13.50
Unexpected axial chirality behaviour: Thinking outside the box for the improvement of Lartesertib synthesis
Nunzia Langella, Merck, Italy
14.30
Data-driven chemistry
Prof Jonathan M. Goodman, University of Cambridge
15.10
Refreshment break and exhibition
CHAIRPERSON: Matt Burns, AstraZeneca, UK
15.40
Approaches to nitrosamines risk assessments and control strategies
Paula Tomlin, AstraZeneca, UK
16.20
Process Chemistry Award winner 2024: Development of processes for the radiolabelling of APIs and methods for the sustainable introduction of fluorine into organic molecules
Prof Véronique Gouverneur, University of Oxford, UK
17.20
Closing remarks
17.30
Wine reception sponsored by Evotec (until 18.15)
19.00
Symposium dinner

Friday 12 April

CHAIRPERSON: Hazmi Tajuddin, Syngenta, UK
09.00
Rapid scale-up of a novel photochemical C–N oxidative coupling: capability development and pilot-plant implementation
Stanley Lai, Syngenta, Switzerland
09.40
Sandwich Pfizer Chemical R&D: a Celebration of Innovation
Dr Anna Vicini, Pfizer, UK
10.20
Refreshment break and exhibition
CHAIRPERSON: Richard Horan, GlaxoSmithKline, UK
10.50
Conquering the challenging manufacture and analysis of lipidic palmitoyl ethanolamine prodrug ETX-018810
David Witty, Eliem and Jade Owen, Veranova
11.30
Development of a scalable, sustainable, and economical route to balcinrenone
Dr Zeina Neouchy, AstraZeneca, UK
12.10
Close

SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options. 


Venue and Contact

Churchill College

Storey's Way
Cambridge
CB3 0DS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees

Early bird- ends 30 January 2024
SCI Member - £395
Non-member - £445
SCI Member with ensuite accommodation - £640
Non-member with ensuite accommodation - £690

After early bird
SCI Member - £520
Non-member - £570
SCI Member with ensuite accommodation - £765
Non-member with ensuite accommodation - £815

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process/Deadlines

Booking terms and conditions


CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com


Sponsors

Gold Exhibitor

Silver Exhibitors
  • Almac

  • Pharmaron


Bronze Exhibitors
  • Key Organics

  • ABCR UK

  • Radleys

  • Asymchem

  • Stolichem

  • Navin Molecular

  • ChiralQuest

  • ThalesNano

  • SpiroChem


Organising committee
  • Max Espensen, SCI/Pharmaron

  • Richard Horan, SCI/GlaxoSmithKline

  • Dave Lathbury, SCI/Astute Chemical Development Ltd

  • Hazmi Tajuddin, Syngenta

  • Robert Walton, SCI/Pfizer

  • Hilmar Weinmann, Johnson & Johnson Innovative Medicine

  • Matt Burns, SCI/AstraZeneca